Table 5 Clinical findings of an acute oral toxicity study of optimized nanomatrices (PCD-6).
Observation | Group I (control) | Group II (treated with |
|---|---|---|
Signs of illness | Nil | Nil |
Body weight (kg) | ||
Pretreatment | 2.13 ± 0.04 | 2.07 ± 0.04 |
Day 1 | 2.13 ± 0.01 | 2.04 ± 0.05 |
Day 7 | 2.32 ± 0.05 | 2.03 ± 0.03 |
Day 14 | 2.24 ± 0.02 | 2.06 ± 0.02 |
Water intake (mL) | ||
Pretreatment | 195.11 ± 2.41 | 193.43 ± 1.50 |
Day 1 | 190.24 ± 1.15 | 192.53 ± 2.45 |
Day 7 | 194.36 ± 1.12 | 195.43 ± 2.61 |
Day 14 | 203.21 ± 2.46 | 203.34 ± 3.33 |
Food intake (g) | ||
Pretreatment | 74.14 ± 4.22 | 76.16 ± 2.91 |
Day 1 | 72.60 ± 2.55 | 71.58 ± 2.43 |
Day 7 | 74.12 ± 3.12 | 74.62 ± 4.54 |
Day 14 | 71.16 ± 4.76 | 73.31 ± 4.21 |
Dermal toxicity: dermal irritation | Nil | Nil |
Ocular toxicity: simple irritation or corrosion | Nil | Nil |
Mortality | Nil | Nil |
